Scalable Chromatography for HCMV Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for large-scale purification of human cytomegalovirus (HCMV) particles are inefficient, particularly at manufacturing scales, due to issues with impurity fouling, stability constraints, and reduced yield, especially when dealing with cruder feed streams and higher impurity levels.
Innovation Solution
A two-step chromatography process involving anion exchange chromatography followed by polishing chromatography, using mixed mode or cationic exchange chromatography, along with additional steps like tangential flow filtration and nuclease treatment, to achieve high purity and yield of HCMV particles suitable for vaccine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If centrifugation-based methods such as density gradient sedimentation are used, then purification effectiveness is improved, but scalability to manufacturing scale is limited
Solution Approach 1:
The patent replaces centrifugation-based mechanical separation methods with chromatography-based separation methods. Specifically, it uses anion exchange chromatography followed by cation exchange chromatography to purify HCMV particles, substituting the mechanical centrifugal force system with a chemical chromatography system that is more suitable for manufacturing scale.
Solution Approach 2:
The patent changes the separation parameters from density-based centrifugation to charge-based chromatography. By exploiting the surface charge properties of HCMV particles through controlled pH and ionic strength conditions during chromatography steps, the process achieves both high purification effectiveness and scalability to manufacturing scale.
2Productivity
If filtration methods are used, then manufacturing scalability is improved, but effectiveness and efficiency decrease with cruder feed streams having higher levels of impurities
Solution Approach 1:
The patent applies preliminary anion exchange chromatography to remove major impurities before the final purification step. This preliminary action reduces the impurity load on subsequent filtration and cation exchange steps, preventing filter fouling and maintaining high purification effectiveness throughout the manufacturing-scale process.
Solution Approach 2:
The patent introduces anion exchange chromatography as an intermediary step between crude harvest and final purification. This intermediate purification step acts as a mediator that reduces impurity levels to a point where subsequent filtration and cation exchange steps can operate efficiently without fouling, bridging the gap between crude feed and high-purity product.
3Productivity
If chromatography is used for purification, then scalability is improved, but capacity and yield decrease due to narrow stability range and large particle size
Solution Approach 1:
The patent optimizes chromatography parameters including pH, ionic strength, and buffer composition to expand the stability range for HCMV particles during chromatography. By carefully controlling these parameters, the process maintains high chromatography capacity and yield while achieving manufacturing-scale purification.
Solution Approach 2:
The patent uses anion exchange chromatography as an intermediary step that prepares the feed stream for subsequent cation exchange chromatography. This two-step approach distributes the purification burden across two specialized steps, with each step optimized for specific impurity removal, thereby maintaining high overall capacity and yield.
4Manufacturing precision
If mixed mode chromatography resin is used, then HCMV flows through the resin achieving high purity, but process complexity increases
Solution Approach 1:
The patent segments the purification process into distinct functional steps: anion exchange chromatography for initial purification, followed by cation exchange chromatography for final polishing. This segmentation allows each step to be optimized for its specific function while maintaining overall process simplicity and high purity output.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high protein purity (>80%) and yield (>40%) of HCMV particles, effectively removing host cell contaminants and ensuring low levels of host cell DNA, making it suitable for commercial vaccine production while maintaining sterility and scalability.
Implementation Method 1
contacting the cell culture medium comprising HCMV to an anion exchange chromatography medium under conditions that allow the HCMV to bind to the anion exchange chromatography medium
Implementation Method 2
contacting the eluate with a polishing chromatography medium selected from a mixed mode chromatography medium and a cationic exchange chromatography medium
Implementation Method 3
the mixed mode chromatography resin has size exclusion properties and the HCMV is excluded from the mixed mode chromatography resin
Data Source
AI summary
The present invention relates to a scalable process for the purification of human cytomegalovirus particles from cell culture medium. In particular, the process involves a two step chromatography process starting with an anion exchange chromatography step followed by a polishing chromatography step selected from mixed mode chromatography or cation exchange chromatography.